North America

Mon
18
Mar

Science says you probably aren't storing your weed the right way

Mon
18
Mar

Buy this, not that: The marijuana stock edition

There's little doubt that the fast-paced marijuana industry has the undivided attention of Wall Street and investors. This year alone, global sales growth in the industry is expected to clock in at 38%, with revenue expected to hit as high as $75 billion by 2030, up from less than $10 billion globally in 2017.

On the surface, it would appear as if nothing could possibly go wrong for the cannabis industry. After all, support for legalization in the U.S. is at an all-time high, and Canada became the first industrialized country in the world to greenlight recreational weed in October. This move by Canada is a blueprint that other developed nations can potentially follow.

Mon
18
Mar

3 marijuana stocks with a killer advantage

Let's face it: Marijuana is a commodity. That makes it challenging for marijuana businesses to differentiate themselves from the competition. But it's not impossible to do so.

Actually, three marijuana stocks appear to be in great shape to stand out from the pack for a long time to come. You could even say that Canopy Growth (NYSE:CGC), Cronos Group (NASDAQ:CRON), and Scotts Miracle-Gro (NYSE:SMG) have a killer advantage. Here's why.

Fri
15
Mar

A greener green: Solar power the best option for cannabis sustainability

Most cannabis producers would consider themselves ecologically responsible. They strive for sustainability by embracing organic grow practices whenever they can. They take pride in supplying a natural product that comes directly from the earth.

Even those who aren’t thinking about sustainability will at least pay it lip service. They know that the environmentally aware crowd is well represented among cannabis consumers and advocates. Eco-conscious investors are increasingly including cannabis stocks in their green portfolios.

Fri
15
Mar

Study finds medical marijuana alleviates seniors’ pain, reduces opioid use

Baby Boomers are spending more on marijuana than any other group in the U.S., and for a simple reason: the growing recognition among seniors and their caregivers that cannabis is an effective and safe alternative medicine. And thanks to the work of a team of neurological researchers in New York, there’s new evidence to support that conclusion. Their preliminary study of more than 200 elderly (75+) pain patients found that medical cannabis both reduced pain symptoms and reduced patients use of opioid painkillers.

Fri
15
Mar

How strain patents could shape the future of cannabis

Cannabis breeders have been at the forefront of the genetic boom that now boasts hundreds of varieties, not to mention millions in tax revenue, but they haven’t always been able to use legal methods to distinguish their hard work and results, writes Danielle Guercio. Yet, as the industry matures, an ever-expanding index of the cannabis plant's unique expressions will be driving medical research and big recreational capital — but who will be holding the paperwork?

Fri
15
Mar

The largest U.S. marijuana deal in history was just announced

Big things are afoot in the marijuana industry. Following the legalization of recreational pot in Canada this past October, the legal weed industry has been validated like never before. As a result, global sales projections for cannabis are going through the roof. Some investment banks on Wall Street predict that annual sales could hit as high as $75 billion by 2030.

Fri
15
Mar

Cannabis player EnWave posts revenue growth of 73%

EnWave (TSXV:ENW) (NASDAQOTH:NWVCF) recently reported first-quarter results for fiscal 2019. Revenue soared 73% year over year, and, as with last quarter, earnings per share came in at breakeven.  

The Canada-based company makes all-natural dried cheese snacks and licenses, manufactures, and installs equipment for dehydrating organic materials, including cannabis. Its stock is listed on Canada's TSX Venture Exchange (along with the Frankfurt Stock Exchange), and also trades over the counter (OTC) in the U.S. 

Fri
15
Mar

Did this deal just make marijuana stock HEXO a bargain?

Canada's biggest marijuana stocks get the most attention. But the global marijuana market is worth $150 billion annually, and that suggests there's plenty of room for smaller pot stocks, including HEXO (NYSEMKT:HEXO). HEXO has been running under the radar compared to Goliaths Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB); however, that could change following HEXO's decision to acquire Newstrike Brands for $263 million in shares. Is HEXO now a bargain worth buying?

Thu
14
Mar

Medical marijuana and liver disease: What science says is possible

Liver disease occurs when the liver experiences a high amount of tissue scarring. This is typically a direct result of constant inflammation and the death of vital cells. This disease inflicts more than 400,000 people each year and is ranked among the top 10 leading causes of death in the U.S.

However, for a disease with such an ugly outcome, a pretty solution may be in the near future.

Pages

Subscribe to RSS - North America